(Q33402191)

26 July 2017

title

Revised recommendations for the management of Gaucher disease in children (English)

1 reference

26 July 2017

1 reference

Ian J Cohen

11

0 references

Martina Huemer

object named as

Martina Huemer

6

0 references

Marianne Rohrbach

object named as

Marianne Rohrbach

9

0 references

author name string

Paige Kaplan

1

1 reference

26 July 2017

Hagit Baris

2

1 reference

26 July 2017

Linda De Meirleir

3

1 reference

26 July 2017

Maja Di Rocco

4

1 reference

26 July 2017

Amal El-Beshlawy

5

1 reference

26 July 2017

Ana Maria Martins

7

1 reference

26 July 2017

Ioana Nascu

8

1 reference

26 July 2017

Lynne Steinbach

10

1 reference

26 July 2017

publication date

8 July 2012

1 reference

European Journal of Pediatrics

26 July 2017

published in

1 reference

26 July 2017

volume

172

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

447-458

1 reference

https://scigraph.springernature.com/pub.10.1007/s00431-012-1771-z

26 July 2017

exact match

0 references

cites work

Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Bone complications in children with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Laboratory and genetic evaluation of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Pathological findings in Gaucher disease type 2 patients following enzyme therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Gaucher's disease: clinical features and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Withdrawal of enzyme replacement therapy in Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Effective cell and gene therapy in a murine model of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Remaining problems in the management of patients with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Phenotype, diagnosis, and treatment of Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Gaucher disease and the synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Clinical and genetic characteristics of Korean patients with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Red and yellow marrow in the femur: age-related changes in appearance at MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Reference values for lysosomal enzymes activities using dried blood spots samples - a Brazilian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Therapeutic goals in the treatment of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Partial splenic embolization in a child with Gaucher disease, massive splenomegaly and severe thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

KIDSCREEN-52 quality-of-life measure for children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Gaucher disease and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Bone events and evolution of biologic markers in Gaucher disease before and during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

The PedsQL as a pediatric patient-reported outcome: reliability and validity of the PedsQL Measurement Model in 25,000 children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Attitudes of couples identified through screening as carriers of Gaucher disease type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00431-012-1771-Z

Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease

21 January 2018

1 reference

12 December 2020

High frequency of mutation G377S in Brazilian type 3 Gaucher disease patients

1 reference

12 December 2020

Fractures in children who have Gaucher disease

1 reference

12 December 2020

Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population

1 reference

12 December 2020

Reply to a commentary by elstein et al. on the paper by cohen et al. in BCMD 24:296-302, 1998

1 reference

12 December 2020

Management of neuronopathic Gaucher disease: revised recommendations

1 reference

12 December 2020

Diagnosis of severe type 1 Gaucher's disease before irreversible damage occurs : is HDL cholesterol the answer?

1 reference

12 December 2020

Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase

1 reference

12 December 2020

Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy

1 reference

12 December 2020

Sequence and rate of bone marrow conversion in the femora of children as seen on MR imaging: are accepted standards accurate?

1 reference

12 December 2020

CCL18 as an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency

1 reference

12 December 2020

Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease

1 reference

12 December 2020

Bone scans in the diagnosis of bone crisis in patients who have Gaucher disease

1 reference

12 December 2020

Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience

1 reference

12 December 2020

Replacement therapy with imiglucerase for type 1 Gaucher's disease

1 reference

12 December 2020

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

12 December 2020

Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease

1 reference

12 December 2020

Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy

1 reference

12 December 2020

Gaucher disease: enzyme therapy in the acute neuronopathic variant

1 reference

12 December 2020

10.1007/S00431-012-1771-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1044668917

0 references

1 reference